Astute Medical Announces NephroCheck Test Presentations At The Society Of Critical Care Medicine Congress

SAN DIEGO, Jan. 17, 2017 /PRNewswire/ -- In a preview of the upcoming Society of Critical Care Medicine's (SCCM) 46^th Annual Congress, Astute Medical, Inc., developer of the NephroCheck Test, today highlighted events studying current and potential applications of the test, which identifies hospital patients at risk of developing moderate to severe acute kidney injury (AKI). The meeting will take place this month at the Hawaii Convention Center in Honolulu from January 21 through January 25.

AKI is one of the top 10 hospital in-patient complications most likely to affect mortality, length of stay and cost.¹ Until now, the lack of predictive diagnostic tools has routinely prevented physicians from identifying high-risk patients and initiating kidney-sparing strategies before damage occurs.²

The NephroCheck Test measures two biomarkers, TIMP-2 and IGFBP-7, capable of detecting kidney stress indicative of AKI risk.³ Physicians can use the test to identify patients at risk of developing moderate to severe AKI and manage them accordingly with the goal of preventing AKI and the resultant loss of kidney function.⁴

Society of Critical Care Medicine Congress attendees can learn more about the NephroCheck Test at Astute Medical's exhibition booth #0822. 

Details of the presentations follow:

The Society of Critical Care Medicine's (SCCM) 46^th Critical Care Congress is the largest critical care event, bringing together all members of the multiprofessional, multidisciplinary team. The five-day event features members of internationally renowned faculty and content sessions that highlight the most up-to-date, evidence-based developments in critical care medicine. 

Important Information About The NephroCheck Test
The NephroCheck Test System is intended to be used in conjunction with clinical evaluation in patients who currently have or have had within the past 24 hours acute cardiovascular and or respiratory compromise and are intensive care unit (ICU) patients as an aid in the risk assessment for moderate or severe AKI within 12 hours of patient assessment. The NephroCheck Test System is intended to be used in patients 21 years of age or older.

About Astute Medical, Inc.
Astute Medical is devoted to improving patient healthcare outcomes through the identification and validation of novel biomarkers.

The company's focus is community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. Astute Medical's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis.

Astute Medical has developed the NephroCheck Test for use in determining whether a hospitalized patient is at risk of developing moderate to severe AKI in the 12 hours following test administration. Early knowledge that a patient is likely to develop AKI may prompt closer patient surveillance and help prevent permanent kidney damage or death.

The company is a founding corporate partner of 0by25, a human rights initiative aimed at eliminating preventable and treatable deaths from AKI worldwide by 2025.

Astute Medical's NephroCheck Test received 510(k)-clearance through FDA's de novo classification pathway. The test is CE-marked and available in Europe.

For additional information, please visit AstuteMedical.com.

Astute Medical^®, the AM logo, Astute140^®, NephroCheck^®, the NephroCheck^® logo, and AkiRisk^® are registered trademarks of Astute Medical, Inc. in the United States. For information regarding trademarks and other intellectual property applicable to this product, including international trademarks, please see www.AstuteMedical.com/US/About/IntellectualProperty. PN0612 Rev A 2017/01/10

¹ Premier, Inc. Complications Research: Identifying hospital-wide harm associated with increased cost, length of stay and mortality in U.S. hospitals. June 2014.
² McCullough PA et al. Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference. Contrib Nephrol. 2013;182:13-29.
³ Kellum JA, Chawla LS. Cell-cycle arrest and acute kidney injury: the light and dark sides. Nephrol Dial Transplant (2015) 0: 1–7doi: 10.1093/ndt/gfv130.
⁴ Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter., Suppl. 2013; 3:1-150.

SOURCE Astute Medical, Inc.